F S&P 500
5,108.75 +17.25 (+0.34%) F Dow Jones
38,625.00 +243.00 (+0.63%) F Nasdaq
17,762.25 +112.50 (+0.64%) E-mini Russell 2000 Index Futur
2,026.90 -0.30 (-0.01%) Petróleo
79.32 +0.37 (+0.47%) Oro
2,313.10 +3.50 (+0.15%)
Cidara Therapeutics, Inc. (CDTX)
Fuera de horario:
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 69
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, CEO & Executive Director | 603.7k | N/D | 1955 |
| Mr. Shane M. Ward | Chief Legal Officer,Corporate Secretary & COO | 464.54k | N/D | 1975 |
| Dr. Taylor Sandison M.D., M.P.H. | Chief Medical Officer | 497k | N/D | 1972 |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 333.31k | N/D | 1977 |
| Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Business Officer & Principal Accounting Officer | 577.85k | N/D | 1973 |
| Ms. Allison Lewis CCP, SPHR | Senior Vice President of People & Culture | N/D | N/D | N/D |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer | 845.1k | N/D | 1968 |
| Ms. Laura A. Navalta | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
| Dr. Nicole Davarpanah J.D., M.D. | Senior VP of Translational Research & Development | N/D | N/D | N/D |
Descripción
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Cidara Therapeutics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 6; Derechos del accionista: 8; Compensación: 9.
